@article {7683,
	title = {Molecularly targeted therapies in unresectable-metastatic gastric cancer. A systematic review},
	journal = {Cancer Treatment Reviews},
	volume = {37},
	year = {2011},
	note = {Cited By :24Export Date: 21 February 2017},
	month = {2011},
	pages = {599 - 610},
	abstract = {Gastric cancer is the second leading cause of cancer related-death. Most patients present with an advanced stage of disease that has a dismal outcome. Evidently, there is a clear need for the development of new agents with novel mechanisms of action in the treatment of this disease. A number of biological agents modulating different signal transduction pathways are currently in clinical development, such as angiogenesis inhibitors and agents targeting epidermal growth factor receptor, cell cycle, matrix metalloproteinases, cyclooxygenase-2 (COX-2), mammalian target of rapamycin (mTOR) or proteasome. This is the first systematic review of the literature to synthesize all available data coming from trials and evaluate the efficacy and safety of molecular targeted drugs in unresectable and metastatic gastric cancer. As knowledge accumulates on the molecular mechanisms underlying carcinogenesis in the stomach, the anticipated development and assessment of molecularly targeted agents may offer a promising perspective for a disease which, to date, remains incurable. {\textcopyright} 2011 Elsevier Ltd.},
	keywords = {Gastric cancer, Molecularly targeted agents, Target therapy},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-80054071524\&doi=10.1016\%2fj.ctrv.2011.03.007\&partnerID=40\&md5=b46dfac4e7660ad49c72a1420d3ed778},
	author = {Zagouri, F. and Papadimitriou, C.A. and Dimopoulos, M.-A. and Pectasides, D.}
}
